MedTrace Logo

R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma

NCT05345158 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-12-19

No results posted yet for this study

Summary

This study will investigate the safety and efficacy of using robotic retroperitoneal lymph node dissection (R-RPLND), a minimally invasive surgical approach, as the first-line of treatment for stage IIA/B (or equivalent) seminoma patients. R-RPLND will be trialed as an alternative to chemotherapy, radiation therapy (for seminoma patients) and open RPLND in this study.

Conditions

  • Lymphadenopathy Retroperitoneal
  • Stage II Testicular Seminoma

Interventions

PROCEDURE

Robotic Retroperitoneal Lymph Node Dissection (RPLND)

Robotic RPLND performed using the DaVinci robotic surgical system.

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Robert Hamilton, MD · The Princess Margaret Cancer Foundation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-23
Primary Completion
2030-11-30
Completion
2030-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05345158 on ClinicalTrials.gov